Clinical trials: Early Rheumatoid Arthritis
Rheumatoid Arthritis
SBD121, a Synbiotic Medical Food for RA Management
The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the dietary management of symptoms of early rheumatoid…
- Trial name
- NCT06005220
- Testing
- SBD121
- Where
- 22 sites in Australia, Bulgaria and 2 more
- Volunteers
- 143 people
- Sponsor
- Solarea Bio, Inc
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Rheumatoid Arthritis
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an…
- Trial name
- NCT04909801
- Testing
- Abatacept, Adalimumab, Methotrexate
- Where
- 75 sites in United States, Argentina and 12 more
- Volunteers
- 338 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).
- Trial name
- OPTIMA (NCT00420927)
- Testing
- adalimumab, methotrexate
- Where
- 170 sites in United States, Argentina and 19 more
- Volunteers
- 1,032 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis
To compare the effects of the combination of ETN and MTX to MTX alone on radiographic change and clinical disease activity in subjects with early RA over 12 months.
- Trial name
- NCT00195494
- Testing
- Etanercept, Methotrexate
- Where
- United States
- Volunteers
- 542 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced…
- Trial name
- RADAR (NCT01162421)
- Testing
- adalimumab, Methotrexate
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA
A key challenge in the management of patients with Rheumatoid Arthritis (RA) is the early identification of patients that are at risk of developing a severe and destructive disease.
- Trial name
- NCT01078597
- Where
- 4 sites in Ireland
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Arthritis,Rheumatoid
Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients
To determine if early clinical response at 12 weeks to Certolizumab Pegol (CZP, Cimzia ®) therapy in adult Rheumatoid Arthritis (RA) patients is a predictor of better long term clinical response at 18 months compared with a lack…
- Trial name
- RA-PROACTIVE (NCT01288287)
- Where
- 22 sites in Ireland, United Kingdom
- Volunteers
- 149 people
- Sponsor
- UCB Pharma
Arthritis Rheumatoid
This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.
This study is to investigate the effect of etanercept in early versus delayed referral for management of rheumatoid arthritis patients assessing real-world patient data entered in the Iraq National Center of Rheumatology database…
- Trial name
- NCT04267614
- Testing
- Etanercept
- Where
- Iraq
- Volunteers
- 1,226 people
- Sponsor
- Pfizer
Osteoarthritis, Rheumatoid Arthritis
Tritanium® Study in Japan
The purpose of this study is to evaluate early fixation and stability of the Tritanium cup. It is expected that the Tritanium® cup will be equal to or better than conventional cementless cups in early fixation/stability and meet…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis of the Femoral Head
- Trial name
- NCT02552069
- Testing
- Tritanium® cup
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Stryker Japan K.K.
Rheumatoid Arthritis
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Phase IIIb study to determine early response to Certolizumab Pegol (CZP) with Magnetic Resonance Imaging (MRI) score Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials (OMERACT) RA MRI Scoring System (RAMRIS) in…
- Trial name
- MARVELOUS (NCT01235598)
- Testing
- Certolizumab Pegol (CZP) 200 mg, Certolizumab Pegol (CZP) 400 mg
- Where
- 10 sites in Denmark, Netherlands and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Pharma
Still's Disease, Adult-Onset
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
The objective of this study is to assess safety, tolerability and early signs of efficacy of the investigational drug Tadekinig alfa in Adult-onset Still's disease, a rare polygenic auto-inflammatory disorder for which treatment…
- Trial name
- NCT02398435
- Testing
- Tadekinig alfa (recombinant human IL-18 binding protein)
- Where
- 20 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- AB2 Bio Ltd.
Rheumatoid Arthritis
Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve.
- Trial name
- NCT01164579
- Testing
- Tasocitinib plus Methotrexate
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA)…
- Trial name
- TELLUS (NCT02393378)
- Testing
- Namilumab, Adalimumab, Methotrexate
- Where
- 13 sites in Czechia, Estonia and 3 more
- Volunteers
- 7 people
- Sponsor
- Takeda
Early Rheumatoid Arthritis
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy…
- Trial name
- PREMIER (NCT00195663)
- Testing
- Adalimumab, Methotrexate
- Where
- 123 sites in United States, Australia and 17 more
- Volunteers
- 799 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis
Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Rheumatoid Arthritis
- Trial name
- ReAct (NCT00650026)
- Testing
- adalimumab
- Sponsor
- Abbott
Rheumatoid Arthritis
Comorbidities and Outcomes in Early Rheumatoid Arthritis
Identify the burden of comorbidity at the time of diagnosis of rheumatoid arthritis. Identify the impact of comorbidity present at diagnosis on cardiovascular disease, death, rheumatoid arthritis disease progression and…
- Trial name
- NCT03675516
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 13,182 people
- Sponsor
- Momentum Data
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 [NCT01519791].
- Trial name
- C-early (NCT01521923)
- Testing
- Certolizumab Pegol + Methotrexate (MTX)
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 359 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This single arm study will assess the effect of tocilizumab + DMARDs (Disease Modifying Anti-Rheumatic Drugs)on improvement of anemia and fatigue in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00951275
- Testing
- tocilizumab [RoActemra/Actemra], Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
- Where
- 27 sites in Italy
- Volunteers
- 105 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
- Trial name
- NCT05246280
- Testing
- TC99m-tilmanocept
- Where
- 13 sites in United States
- Volunteers
- 169 people
- Sponsor
- Navidea Biopharmaceuticals